Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Beholder  – Russia, 2019-11-19 14:39  – Posting: # 20828
Views: 1,128

» We don't know nothing about new FDC - no safety, no efficacy data. This is new drug.

Why no safety and efficacy data!? Lets take abovementioned examples:

Amlodipine + Indapamide + Perindopril - here
Losartan + Amlodipine + Rosuvastatin - here.
Indapamide + Rosuvastatin + Perindopril here.

So, can we say that "In all cases, the established regime has a well-characterized safety and efficacy profile..." and proceed with Scenario 2 comparing triple combination with two reference drugs?!

Best regards
Beholder

Complete thread:

Activity
 Admin contact
20,255 posts in 4,263 threads, 1,398 registered users;
online 17 (0 registered, 17 guests [including 13 identified bots]).
Forum time (Europe/Vienna): 11:54 CET

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5